Palisade Bio provides corporate update, reiterated upcoming milestones

Palisade Bio provided a corporate update and reiterated upcoming milestones. Recent Highlights: The formation of the Company’s Clinical Advisory Board and the appointments of preeminent Key Opinion Leaders, Bruce Sands, MD, MS and Floria Rieder, MD; The exercise of outstanding common stock warrants resulting in gross proceeds of $2.5 million; Presentation of positive preclinical data of lead asset, PALI-2108, at the 2024 Crohn’s & Colitis Congress; and Receipt of the second milestone payment to our joint development partner, Giiant Pharma, from the US Crohn’s and Colitis Foundation, through its Inflammatory Bowel Disease Ventures program. Upcoming Milestones: Ongoing IND/CTA-enabling tox studies; Complete nonclinical IND/CTA-enabling activities by the end of the third quarter of 2024; Submit initial IND/CTA prior to the end of 2024; and Initiate Phase 1a/b before the end of 2024.